Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Biliary Tract Diseases

Free Subscription Articles published in Hepatology Retrieve available abstracts of 183 articles: HTML format

Single Articles

May 2023
1. NEJAK-BOWEN K, Monga SP
   Wnt-beta-catenin in hepatobiliary homeostasis, injury, and repair.
   Hepatology. 2023 May 30. doi: 10.1097/HEP.0000000000000495.
   PubMed     Abstract available
   
   
   
2. 
   Erratum: IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
   Hepatology. 2023 May 15. doi: 10.1097/HEP.0000000000000040.
   PubMed    
   
   
   
3. SHU L, Li X, Liu Z, Li K, et al
   Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.
   Hepatology. 2023 May 5. doi: 10.1097/HEP.0000000000000437.
   PubMed     Abstract available
   
   
   
4. JEONG H, Kim KP, Jeong JH, Hwang DW, et al
   Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
   Hepatology. 2023;77:1540-1549.
   PubMed     Abstract available
   
   
   
5. FORMAN LM, Sapisochin G, Assis DN, Arrive L, et al
   Reply: Living donor liver transplantation for people with PSC.
   Hepatology. 2023;77:E97-E98.
   PubMed    
   
   
   April 2023
6. MACKOWIAK B, Gao B
   Activation of cholangiocyte mTORC1 drives alcohol-induced ductular reaction.
   Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000416.
   PubMed    
   
   
   
7. RUSSI AE, Shivakumar P, Luo Z, Bezerra J, et al
   Plasticity between ILC2 subsets and amphiregulin expression regulate epithelial repair in biliary atresia.
   Hepatology. 2023 Apr 21. doi: 10.1097/HEP.0000000000000418.
   PubMed     Abstract available
   
   
   
8. DANIEL N, Genua F, Jenab M, Mayen AL, et al
   The role of the gut microbiome in the development of hepatobiliary cancers.
   Hepatology. 2023 Apr 15. doi: 10.1097/HEP.0000000000000406.
   PubMed     Abstract available
   
   
   
9. HARTL L, Reiberger T, Trauner M
   Reply: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
   Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000399.
   PubMed    
   
   
   
10. UMAR S, Nadeem A, Nadeem M
    Letter to the editor: progressive cholestasis and associated sclerosing cholangitis are complications of COVID-19 in patients with chronic liver disease.
    Hepatology. 2023 Apr 11. doi: 10.1097/HEP.0000000000000398.
    PubMed    
    
    
    
11. YOO C, Javle MM, Verdaguer Mata H, de Braud F, et al
    Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000365.
    PubMed     Abstract available
    
    
    
12. CABALLERO-CAMINO FJ, Rodrigues PM, Wangsell F, Agirre-Lizaso A, et al
    A3907, a systemic ASBT inhibitor, improves cholestasis in mice by multi-organ activity and shows translational relevance to humans.
    Hepatology. 2023 Apr 3. doi: 10.1097/HEP.0000000000000376.
    PubMed     Abstract available
    
    
    
13. SINGH SP, Mondia N
    Letter to the Editor: Much more needed in natural history of Alagille syndrome.
    Hepatology. 2023;77:E78.
    PubMed    
    
    
    March 2023
14. HARTMANN P, Schnabl B
    Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?
    Hepatology. 2023;77:709-711.
    PubMed    
    
    
    February 2023
15. MAMMADOV RA, Visseren T, Roest HP, van der Laan LJW, et al
    Letter to Editor: the mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. is the dysbiosis index really predictive for the recurrence of psc?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000338.
    PubMed    
    
    
    
16. LI J, Chen J, Lee PMY, Zhang J, et al
    Familial clustering of intrahepatic cholestasis of pregnancy: A nationwide population-based study in Denmark.
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000328.
    PubMed     Abstract available
    
    
    
17. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    Reply: The mucosal gut signature in primary sclerosing cholangitis before and after liver transplantation. Is the dysbiosis index really predictive for the recurrence of PSC?
    Hepatology. 2023 Feb 24. doi: 10.1097/HEP.0000000000000340.
    PubMed    
    
    
    
18. ZHANG J, Lyu Z, Li B, You Z, et al
    P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000317.
    PubMed     Abstract available
    
    
    
19. KUNDU D, Kennedy L, Zhou T, Ekser B, et al
    p16 INK4A drives non-alcoholic fatty liver disease phenotypes in high fat diet fed mice via biliary e2f1/foxo1/igf-1 signaling.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000307.
    PubMed     Abstract available
    
    
    
20. WU N, Zhou T, Carpino G, Baiocchi L, et al
    Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2-/- mice.
    Hepatology. 2023 Feb 20. doi: 10.1097/HEP.0000000000000310.
    PubMed     Abstract available
    
    
    
21. AMENT CE, Steinmann S, Evert K, Pes GM, et al
    Aberrant fucosylation sustains the NOTCH and EGFR/NF-kB pathways and has a prognostic value in human intrahepatic cholangiocarcinoma.
    Hepatology. 2023 Feb 16. doi: 10.1097/HEP.0000000000000322.
    PubMed     Abstract available
    
    
    
22. VANDRIEL SM, Li LT, She H, Wang JS, et al
    Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA study.
    Hepatology. 2023;77:512-529.
    PubMed     Abstract available
    
    
    
23. HABASH N, Ibrahim SH
    The Global Alagille Alliance study: Redefining the natural history of Alagille syndrome.
    Hepatology. 2023;77:347-349.
    PubMed    
    
    
    January 2023
24. ALI AH, Buness CW, Fischer R, Holtmann GJ, et al
    Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 30. doi: 10.1097/HEP.0000000000000304.
    PubMed    
    
    
    
25. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    Reply: insurance should cover vancomycin for primary sclerosing cholangitis.
    Hepatology. 2023 Jan 26. doi: 10.1097/HEP.0000000000000305.
    PubMed    
    
    
    
26. LAMARCA A, Edeline J
    Adjuvant treatment for biliary tract tumours: lost in a maze?
    Hepatology. 2023 Jan 23. doi: 10.1097/HEP.0000000000000301.
    PubMed    
    
    
    
27. LI Y, Yang B, Miao H, Liu L, et al
    Nicotinamide N-methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000028.
    PubMed     Abstract available
    
    
    
28. UNALP-ARIDA A, Ruhl CE
    Increasing gallstone disease prevalence and associations with gallbladder and biliary tract mortality in the United States.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000264.
    PubMed     Abstract available
    
    
    
29. GUILLOT A, Winkler M, Silva Afonso M, Aggarwal A, et al
    Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression.
    Hepatology. 2023 Jan 13. doi: 10.1097/HEP.0000000000000270.
    PubMed     Abstract available
    
    
    
30. SHORT C, Zhong A, Xu J, Mahdi E, et al
    TWEAK/FN14 promotes profibrogenic pathway activation in Prominin-1-expressing hepatic progenitor cells in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000026.
    PubMed     Abstract available
    
    
    
31. LEE SH, So J, Shin D
    Hepatocyte-to-cholangiocyte conversion occurs through transdifferentiation independently of proliferation in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000016.
    PubMed     Abstract available
    
    
    
32. ZHANG L, Pan Q, Zhang L, Xia H, et al
    Runt-related transcription factor-1 ameliorates bile acid-induced hepatic inflammation in cholestasis through JAK/STAT3 signaling.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000041.
    PubMed     Abstract available
    
    
    
33. HELLEN DJ, Bennett A, Malla S, Klindt C, et al
    Liver-restricted deletion of the biliary atresia candidate gene Pkd1l1 causes bile duct dysmorphogenesis and ciliopathy.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000029.
    PubMed     Abstract available
    
    
    
34. NYHOLM I, Hukkinen M, Pihlajoki M, Davidson JR, et al
    Serum FGF19 predicts outcomes of Kasai portoenterostomy in biliary atresia.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000048.
    PubMed     Abstract available
    
    
    
35. MA J, Yang Z, Huang Z, Li L, et al
    Rngtt governs biliary-derived liver regeneration initiation by transcriptional regulation of mTORC1 and Dnmt1 in zebrafish.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000186.
    PubMed     Abstract available
    
    
    
36. CANTALLOPS VILA P, Ravichandra A, Agirre Lizaso A, Perugorria MJ, et al
    Heterogeneity, crosstalk and targeting of cancer associated fibroblasts in cholangiocarcinoma.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000206.
    PubMed     Abstract available
    
    
    
37. HEINEMANN M, Adam R, Karam V, Schramm C, et al
    Letter to the Editor: Living donor liver transplantation for people with PSC.
    Hepatology. 2023 Jan 3. doi: 10.1097/HEP.0000000000000208.
    PubMed    
    
    
    September 2022
38. BORAD MJ, Bai LY, Richards D, Mody K, et al
    Silmitasertib Plus Gemcitabine and Cisplatin First-Line Therapy in Locally Advanced/Metastatic Cholangiocarcinoma: a Phase 1b/2 Study.
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32804.
    PubMed     Abstract available
    
    
    
39. HARPAVAT S, Hawthorne K, Setchell KDR, Narvaez Rivas M, et al
    Serum Bile Acids as a New Prognostic Biomarker in Biliary Atresia Following Kasai Portoenterostomy.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32800.
    PubMed     Abstract available
    
    
    
40. BIAGIOLI M, Marchiano S, di Giorgio C, Roselli R, et al
    Combinatorial targeting of GPBAR1 and CYSLTR1 reveals a mechanistic role for bile acids and leukotrienes in drug induced liver injury.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32787.
    PubMed     Abstract available
    
    
    
41. BOWLUS CL, Arrive L, Bergquist A, Deneau M, et al
    AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.
    Hepatology. 2022 Sep 9. doi: 10.1002/hep.32771.
    PubMed    
    
    
    
42. LEUNG DH, Devaraj S, Goodrich NP, Chen X, et al
    Serum Biomarkers Correlated with Liver Stiffness Assessed in a Multi-center Study of Pediatric Cholestatic Liver Disease.
    Hepatology. 2022 Sep 7. doi: 10.1002/hep.32777.
    PubMed     Abstract available
    
    
    
43. HOLE MJ, Kaasen Jorgensen K, Holm K, Braadland PR, et al
    A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32773.
    PubMed     Abstract available
    
    
    August 2022
44. MAYO MJ
    Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?
    Hepatology. 2022;76:518-531.
    PubMed     Abstract available
    
    
    
45. ZHANG X, Wang Z, Tang W, Wang X, et al
    Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics.
    Hepatology. 2022;76:317-329.
    PubMed     Abstract available
    
    
    July 2022
46. HEUCKE N, Keitel V
    COVID-19-associated cholangiopathy: What's left after the virus has gone?
    Hepatology. 2022 Jul 13. doi: 10.1002/hep.32668.
    PubMed    
    
    
    
47. HARTL L, Reiberger T, Trauner M
    On the development of secondary sclerosing cholangitis in chronic liver disease patients after COVID-19.
    Hepatology. 2022 Jul 12. doi: 10.1002/hep.32664.
    PubMed    
    
    
    June 2022
48. DENG M, Ran P, Chen L, Wang Y, et al
    Proteogenomic Characterization of Cholangiocarcinoma.
    Hepatology. 2022 Jun 18. doi: 10.1002/hep.32624.
    PubMed     Abstract available
    
    
    
49. 
    Retracted: Posttranslational regulation of polycystin-2 protein expression as a novel mechanism of cholangiocyte reaction and repair from biliary damage.
    Hepatology. 2022 Jun 17. doi: 10.1002/hep.32595.
    PubMed     Abstract available
    
    
    
50. XU J, Wang Y, Khoshdeli M, Peach M, et al
    IL-31 Levels Correlate with Pruritus in Patients with Cholestatic and Metabolic Liver Diseases and is FXR Responsive in NASH.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32599.
    PubMed     Abstract available
    
    
    May 2022
51. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    PubMed     Abstract available
    
    
    
52. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    PubMed     Abstract available
    
    
    
53. ANDERSEN JB
    Stromal yin-yang of myofibroblasts and endothelial cells in the progression of intrahepatic cholangiocarcinoma.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32558.
    PubMed    
    
    
    
54. ZHOU J, Sun Y, Zhang W, Yuan J, et al
    Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis.
    Hepatology. 2022 May 1. doi: 10.1002/hep.32548.
    PubMed     Abstract available
    
    
    April 2022
55. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32543.
    PubMed    
    
    
    
56. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Response to Letter to the editor: For the core set of bile lipidome and meta-proteome signature, repeatability is the key.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32541.
    PubMed    
    
    
    
57. SHCHEYNIKOV N, Boggs K, Green A, Feranchak AP, et al
    Identification of the Chloride Channel, Leucine-Rich Repeat-Containing Protein 8, subfamily A (LRRC8A), in Mouse Cholangiocytes.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32536.
    PubMed     Abstract available
    
    
    
58. MOHAMAD ZAKI NH, Shiota J, Calder AN, Keeley TM, et al
    C-X-C motif chemokine ligand 1 induced by Hedgehog signaling promotes mouse extrahepatic bile duct repair after acute injury.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32492.
    PubMed     Abstract available
    
    
    
59. MANDATO C, Vajro P
    Letter to the Editor: The burgeoning field of Progressive Familial Intrahepatic Cholestasis.
    Hepatology. 2022 Apr 5. doi: 10.1002/hep.32489.
    PubMed    
    
    
    March 2022
60. SHARMA N, Yadav M, Tripathi G, Mathew B, et al
    Bile multi-omics analysis classifies lipid species and microbial peptides predictive of Carcinoma of Gall bladder.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32496.
    PubMed     Abstract available
    
    
    
61. JAVITT NB
    Letter to the Editor: Hyperosmolarity during hepatic bile formation:Overlooked significance.
    Hepatology. 2022 Mar 29. doi: 10.1002/hep.32482.
    PubMed    
    
    
    
62. HENGSTLER JG, Oude Elferink R, van de Graaf SF, Drasdo D, et al
    The de-micellization hypothesis of water influx into bile ducts.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32485.
    PubMed    
    
    
    
63. WANG T, Xu C, Zhang Z, Wu H, et al
    Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32483.
    PubMed     Abstract available
    
    
    
64. BASS LM, Ye W, Hawthorne K, Leung DH, et al
    The Risk of Variceal Hemorrhage and Pre-Transplant Mortality in Children with Biliary Atresia.
    Hepatology. 2022 Mar 10. doi: 10.1002/hep.32451.
    PubMed     Abstract available
    
    
    
65. 
    Erratum for Nevi, et al. DCLK1, a putative stem cell marker in human cholangiocarcinoma.
    Hepatology. 2022;75:773.
    PubMed    
    
    
    
66. IBRAHIM SH, Kamath BM, Loomes KM, Karpen SJ, et al
    Cholestatic Liver Diseases of Genetic Etiology: Advances and Controversies.
    Hepatology. 2022 Mar 1. doi: 10.1002/hep.32437.
    PubMed     Abstract available
    
    
    February 2022
67. WU MJ, Shi L, Merritt J, Zhu AX, et al
    Biology of IDH Mutant Cholangiocarcinoma.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32424.
    PubMed     Abstract available
    
    
    
68. ROBERTS SB, Hirschfield GM, Worobetz LJ, Vincent C, et al
    Ethnicity, disease severity and survival in Canadian patients with Primary Biliary Cholangitis.
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32426.
    PubMed     Abstract available
    
    
    
69. CHAUDHRY HUR, Hayat A, Ahmad A
    Letter to the Editor: Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32416.
    PubMed    
    
    
    
70. JEON Y, Kwon SM, Rhee H, Yoo JE, et al
    Molecular and radio-pathologic spectrum between hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Hepatology. 2022 Feb 5. doi: 10.1002/hep.32397.
    PubMed     Abstract available
    
    
    
71. LUO C, Xin H, Zhou Z, Hu Z, et al
    Tumor-Derived Exosomes Induce Immunosuppressive Macrophages to Foster Intrahepatic Cholangiocarcinoma Progression.
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32387.
    PubMed     Abstract available
    
    
    
72. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available
    
    
    January 2022
73. RUIZ DE GAUNA M, Biancaniello F, Gonzalez-Romero F, Rodrigues PM, et al
    Cholangiocarcinoma progression depends on the uptake and metabolization of extracellular lipids.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32344.
    PubMed     Abstract available
    
    
    
74. ANDERSSON ER
    Outside influence: the extrahepatic duct as a source for bile duct regeneration.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32334.
    PubMed    
    
    
    
75. SHIODE Y, Kodama T, Shigeno S, Murai K, et al
    Traf3 inactivation promotes the development of intrahepatic cholangiocarcinoma via NIK-mediated hepatocyte transdifferentiation.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32317.
    PubMed     Abstract available
    
    
    
76. 
    Retracted: Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies.
    Hepatology. 2022 Jan 7. doi: 10.1002/hep.32246.
    PubMed    
    
    
    December 2021
77. PASTOR CM
    Reply to the review <>.
    Hepatology. 2021 Dec 27. doi: 10.1002/hep.32296.
    PubMed    
    
    
    
78. VARTAK N, Hengstler JG
    REPLY TO HEP-21-2202: Analysis and limits of detection of biliary flux.
    Hepatology. 2021 Dec 25. doi: 10.1002/hep.32297.
    PubMed    
    
    
    
79. MASYUK AI, Masyuk TV, Trussoni CE, Pirius NE, et al
    Autophagy Promotes Hepatic Cystogenesis in Polycystic Liver Disease via Depletion of Cholangiocyte Ciliogenic Proteins.
    Hepatology. 2021 Dec 23. doi: 10.1002/hep.32298.
    PubMed     Abstract available
    
    
    
80. REMETIC J, Ghallab A, Hobloss Z, Brackhagen L, et al
    Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance.
    Hepatology. 2021 Dec 20. doi: 10.1002/hep.32289.
    PubMed     Abstract available
    
    
    
81. SAPISOCHIN G, Ivanics T, Heimbach J
    Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time?
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32258.
    PubMed     Abstract available
    
    
    November 2021
82. RUBINO JG, Flemming JA
    Menopausal hormone therapy and risk of biliary tract cancers: addressing the ant, not the elephant in the room.
    Hepatology. 2021 Nov 25. doi: 10.1002/hep.32254.
    PubMed     Abstract available
    
    
    
83. JACKSON SS, Pfeiffer RM, Gabbi C, Anderson L, et al
    Menopausal hormone therapy and risk of biliary tract cancers.
    Hepatology. 2021 Nov 11. doi: 10.1002/hep.32198.
    PubMed     Abstract available
    
    
    
84. LI H, Lan T, Liu H, Liu C, et al
    IL-6 induced cGGNBP2 encodes a novel protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32232.
    PubMed     Abstract available
    
    
    
85. WU N, Carpino G, Ceci L, Baiocchi L, et al
    MT1 but not MT2 melatonin receptor knockout decreases biliary damage and liver fibrosis during cholestatic liver injury.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32233.
    PubMed     Abstract available
    
    
    
86. LEE BT, Tana MM, Kahn JA, Dara L, et al
    We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
    Hepatology. 2021;74:2876-2887.
    PubMed     Abstract available
    
    
    October 2021
87. ZIMMER CL, Filipovic I, Cornillet M, O'Rourke CJ, et al
    MAIT cell tumor infiltration predicts long-term survival in cholangiocarcinoma.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32222.
    PubMed     Abstract available
    
    
    
88. KONIGSHOFER P, Hofer BS, Brusilovskaya K, Simbrunner B, et al
    Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32220.
    PubMed     Abstract available
    
    
    
89. LINDOR KD, Dawson PA, Trauner M
    Alan Hofmann (1931-2021): A Career Well Spent Understanding Bile Acids.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32206.
    PubMed     Abstract available
    
    
    
90. FAIRFIELD CJ, Drake TM, Pius R, Bretherick AD, et al
    Genome-wide Analysis Identifies Novel Gallstone-susceptibility Loci Including Genes Regulating Gastrointestinal Motility.
    Hepatology. 2021 Oct 15. doi: 10.1002/hep.32199.
    PubMed     Abstract available
    
    
    
91. GRAHAM JJ, Mukherjee S, Yuksel M, Sanabria Mateos R, et al
    Aberrant hepatic trafficking of gut-derived T-cells is not specific to primary sclerosing cholangitis.
    Hepatology. 2021 Oct 11. doi: 10.1002/hep.32193.
    PubMed     Abstract available
    
    
    
92. CHEN L, Yang H, Li H, He C, et al
    Novel insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study.
    Hepatology. 2021 Oct 8. doi: 10.1002/hep.32183.
    PubMed     Abstract available
    
    
    
93. LLEO A, Hirschfield GM
    Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?
    Hepatology. 2021;74:2307.
    PubMed    
    
    
    
94. MA Y, Su H, Yuksel M, Longhi MS, et al
    Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
    Hepatology. 2021;74:2032-2046.
    PubMed     Abstract available
    
    
    September 2021
95. ZHAO C, Lancman JJ, Yang Y, Gates KP, et al
    Intrahepatic cholangiocyte regeneration from an Fgf-dependent extrahepatic progenitor niche in a zebrafish model of Alagille Syndrome.
    Hepatology. 2021 Sep 27. doi: 10.1002/hep.32173.
    PubMed     Abstract available
    
    
    
96. HUNG HY, Wang CC, Wei JC
    Letter to the Editor: Postdiagnosis aspirin use associated with decreased biliary tract cancer?
    Hepatology. 2021 Sep 23. doi: 10.1002/hep.32170.
    PubMed     Abstract available
    
    
    
97. VARTAK N, Hengstler JG
    Response to 21-1766: Challenging the dogma of canalicular bile flow.
    Hepatology. 2021 Sep 21. doi: 10.1002/hep.32168.
    PubMed     Abstract available
    
    
    
98. ZHOU SL, Luo CB, Song CL, Zhou ZJ, et al
    Genomic evolution and the impact of SLIT2 mutation in relapsed intrahepatic cholangiocarcinoma.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32164.
    PubMed     Abstract available
    
    
    
99. JAVITT NB, Boyer JL
    Letter to the Editor: On the Mechanisms of Biliary Flux.
    Hepatology. 2021 Sep 20. doi: 10.1002/hep.32167.
    PubMed     Abstract available
    
    
    
100. DE JONG IEM, Overi D, Carpino G, Gouw ASH, et al
     Persistent Biliary Hypoxia and Lack of Regeneration Are Key Mechanisms in the Pathogenesis of Post-transplant Non-anastomotic Strictures.
     Hepatology. 2021 Sep 20. doi: 10.1002/hep.32166.
     PubMed     Abstract available
     
     
     
101. CARAPETO F, Bozorgui B, Shroff RT, Chagani S, et al
     The Immunogenomic Landscape of Resected Intrahepatic Cholangiocarcinoma.
     Hepatology. 2021 Sep 12. doi: 10.1002/hep.32150.
     PubMed     Abstract available
     
     
     
102. AN J, Kim D, Oh B, Oh YJ, et al
     Comprehensive characterization of viral integrations and genomic aberrations in HBV-infected intrahepatic cholangiocarcinomas.
     Hepatology. 2021 Sep 3. doi: 10.1002/hep.32135.
     PubMed     Abstract available
     
     
     
103. WANG SS, Tang XT, Lin M, Yuan J, et al
     Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.
     Hepatology. 2021;74:1578-1594.
     PubMed     Abstract available
     
     
     
104. WANG Y, Hylemon PB, Zhou H
     Long Noncoding RNA H19: A Key Player in Liver Diseases.
     Hepatology. 2021;74:1652-1659.
     PubMed    
     
     
     August 2021
105. VEDELD HM, Grimsrud MM, Andresen K, Pharo HD, et al
     Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.
     Hepatology. 2021 Aug 26. doi: 10.1002/hep.32125.
     PubMed     Abstract available
     
     
     
106. LINDOR KD, Bowlus CL, Boyer J, Levy C, et al
     Primary Biliary Cholangitis: 2021 Practice Guidance Update from the American Association for the Study of Liver Diseases.
     Hepatology. 2021 Aug 24. doi: 10.1002/hep.32117.
     PubMed     Abstract available
     
     
     
107. ARORA M, Bogenberger JM, Abdelrahman AM, Yonkus J, et al
     Synergistic Combination of Cytotoxic Chemotherapy and Cyclin Dependent Kinase 4/6 Inhibitors in Biliary Tract Cancers.
     Hepatology. 2021 Aug 18. doi: 10.1002/hep.32102.
     PubMed     Abstract available
     
     
     
108. AMARACHINTHA SP, Mourya R, Ayabe H, Yang L, et al
     Biliary organoids uncover delayed epithelial development and barrier function in biliary atresia.
     Hepatology. 2021 Aug 15. doi: 10.1002/hep.32107.
     PubMed     Abstract available
     
     
     
109. EL KASMI KC, Ghosh S, Anderson AL, Devereaux MW, et al
     Pharmacologic Activation of Hepatic Farnesoid X Receptor Prevents Parenteral Nutrition Associated Cholestasis in Mice.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32101.
     PubMed     Abstract available
     
     
     
110. LIN Y, Cai Q, Chen Y, Shi T, et al
     CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma via 5-lipoxygenase.
     Hepatology. 2021 Aug 13. doi: 10.1002/hep.32099.
     PubMed     Abstract available
     
     
     
111. ZENG R, Sha W, Leung FW, Chen H, et al
     Letter to the Editor: Proton pump inhibitors and Biliary Tract Cancer Risk: Causality or Reverse Causality?
     Hepatology. 2021 Aug 5. doi: 10.1002/hep.32090.
     PubMed     Abstract available
     
     
     July 2021
112. PANT K, Peixoto E, Richard S, Biswas A, et al
     Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
     Hepatology. 2021 Jul 29. doi: 10.1002/hep.32080.
     PubMed     Abstract available
     
     
     
113. CAI P, Mao X, Zhao J, Nie L, et al
     Farnesoid X Receptor is Required for the Redifferentiation of Bi-potential Progenitor Cells during Biliary-Mediated Zebrafish Liver Regeneration.
     Hepatology. 2021 Jul 28. doi: 10.1002/hep.32076.
     PubMed     Abstract available
     
     
     
114. WADHWANI SI, Gottlieb L, Bucuvalas JC, Lyles C, et al
     Addressing social adversity to improve outcomes for children after liver transplant.
     Hepatology. 2021 Jul 28. doi: 10.1002/hep.32073.
     PubMed     Abstract available
     
     
     
115. GHOSH S, Devereaux MW, Anderson AL, Gehrke S, et al
     NFkappaB regulation of LRH-1 and ABCG5/8 potentiates phytosterol role in the pathogenesis of parenteral nutrition associated cholestasis.
     Hepatology. 2021 Jul 26. doi: 10.1002/hep.32071.
     PubMed     Abstract available
     
     
     
116. LOBE C, Vallette M, Arbelaiz A, Gonzalez-Sanchez E, et al
     ZEB1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling.
     Hepatology. 2021 Jul 23. doi: 10.1002/hep.32069.
     PubMed     Abstract available
     
     
     
117. ZHANG JW, Yang X, Ding HR, Zhang L, et al
     Is aspirin a drug or just a marker for biliary cancer?
     Hepatology. 2021 Jul 9. doi: 10.1002/hep.32052.
     PubMed     Abstract available
     
     
     
118. LEE MH, Huang YH, Koshiol J
     Response Letter Regarding Article, "Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort".
     Hepatology. 2021 Jul 8. doi: 10.1002/hep.32051.
     PubMed     Abstract available
     
     
     
119. DE GOEIJ FHC, Schlegel A, Muiesan P, Guarrera JV, et al
     Hypothermic oxygenated machine perfusion protects from cholangiopathy in DCD liver transplantation.
     Hepatology. 2021 Jul 7. doi: 10.1002/hep.32044.
     PubMed     Abstract available
     
     
     
120. WANG H, Song X, Liao H, Wang P, et al
     Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
     Hepatology. 2021;74:248-263.
     PubMed     Abstract available
     
     
     June 2021
121. VARTAK N, Drasdo D, Geisler F, Itoh T, et al
     On the mechanisms of biliary flux.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32027.
     PubMed     Abstract available
     
     
     
122. SHI S, Chen S, Verstegen MMA, Pan Q, et al
     Letter to the Editor: HMGB1 Release is a Newly Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32026.
     PubMed     Abstract available
     
     
     
123. MEADOWS V, Kennedy L, Ekser B, Kyritsi K, et al
     Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis via Farnesoid X Receptor Signaling.
     Hepatology. 2021 Jun 23. doi: 10.1002/hep.32028.
     PubMed     Abstract available
     
     
     
124. BARRON-MILLAR B, Ogle L, Mells G, Flack S, et al
     The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.
     Hepatology. 2021 Jun 15. doi: 10.1002/hep.32011.
     PubMed     Abstract available
     
     
     
125. LEE YT, Wang JJ, Luu M, Noureddin M, et al
     Comparison of Clinical Features and Outcomes between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
     Hepatology. 2021 Jun 11. doi: 10.1002/hep.32007.
     PubMed     Abstract available
     
     
     
126. KYRITSI K, Kennedy L, Meadows V, Hargrove L, et al
     Mast Cells Induce Ductular Reaction Mimicking Liver Injury in Mice Through Mast Cell-Derived Transforming Growth Factor Beta 1 Signaling.
     Hepatology. 2021;73:2397-2410.
     PubMed     Abstract available
     
     
     May 2021
127. LEPORE A, Choy PM, Lee NC, Carella MA, et al
     Phosphorylation and stabilization of PIN1 by JNK promote intrahepatic cholangiocarcinoma growth.
     Hepatology. 2021 May 28. doi: 10.1002/hep.31983.
     PubMed     Abstract available
     
     
     
128. SUN LY, Hu JY, Liang L, Tong XM, et al
     Letter to the Editor: Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?
     Hepatology. 2021 May 22. doi: 10.1002/hep.31916.
     PubMed     Abstract available
     
     
     
129. JOHN BV, Deng Y, Martin P, Levy C, et al
     Response to "Is Male Gender Associated with Increased Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis?"
     Hepatology. 2021 May 22. doi: 10.1002/hep.31917.
     PubMed     Abstract available
     
     
     
130. KAMAL H, Sadr-Azodi O, Engstrand L, Brusselaers N, et al
     Association between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: a Swedish Population-Based Cohort Study.
     Hepatology. 2021 May 21. doi: 10.1002/hep.31914.
     PubMed     Abstract available
     
     
     
131. MARTINEZ M, Perito ER, Valentino P, Mack CL, et al
     Recurrence of primary sclerosing cholangitis after liver transplant in children: an international observational study.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31911.
     PubMed     Abstract available
     
     
     
132. JANSSON H, Sparrelid E
     Letter to the Editor: The role of surgery in multiple intrahepatic cholangiocarcinoma should not be dismissed without further analysis.
     Hepatology. 2021 May 18. doi: 10.1002/hep.31905.
     PubMed     Abstract available
     
     
     
133. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Reply to (20-1119.R1) Surgery for advanced intrahepatic cholangiocarcinoma warrants further investigation.
     Hepatology. 2021 May 17. doi: 10.1002/hep.31904.
     PubMed     Abstract available
     
     
     
134. GENTILINI A, Lori G, Caligiuri A, Raggi C, et al
     Extracellular signal-regulated kinase 5 regulates the malignant phenotype of cholangiocarcinoma cells.
     Hepatology. 2021 May 6. doi: 10.1002/hep.31888.
     PubMed     Abstract available
     
     
     
135. LIAO SF, Koshiol J, Huang YH, Jackson SS, et al
     Postdiagnosis aspirin use associated with decreased biliary tract cancer-specific mortality in a large nationwide cohort.
     Hepatology. 2021 May 3. doi: 10.1002/hep.31879.
     PubMed     Abstract available
     
     
     
136. VAN DER LAAN LJW, Roos FJM, Verstegen MMA
     Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.
     Hepatology. 2021 May 2. doi: 10.1002/hep.31877.
     PubMed     Abstract available
     
     
     April 2021
137. YOON JG, Kim MH, Jang M, Kim H, et al
     Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and PD-1/PD-L1 Blockade Responses.
     Hepatology. 2021 Apr 21. doi: 10.1002/hep.31862.
     PubMed     Abstract available
     
     
     
138. XU Y, Leng K, Yao Y, Kang P, et al
     A Circular RNA, Cholangiocarcinoma-Associated Circular RNA 1, Contributes to Cholangiocarcinoma Progression, Induces Angiogenesis, and Disrupts Vascular Endothelial Barriers.
     Hepatology. 2021;73:1419-1435.
     PubMed     Abstract available
     
     
     
139. OSTROUMOV D, Duong S, Wingerath J, Woller N, et al
     Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
     Hepatology. 2021;73:1399-1418.
     PubMed     Abstract available
     
     
     March 2021
140. DI-LUOFFO M, Pirenne S, Saandi T, Loriot A, et al
     A novel mouse model of cholangiocarcinoma uncovers a role for Tensin-4 in tumor progression.
     Hepatology. 2021 Mar 26. doi: 10.1002/hep.31834.
     PubMed     Abstract available
     
     
     
141. BOERNER T, Drill E, Pak LM, Nguyen B, et al
     Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
     Hepatology. 2021 Mar 25. doi: 10.1002/hep.31829.
     PubMed     Abstract available
     
     
     
142. LUO X, Campbell NA, He L, O'Brien DR, et al
     SULF2 monoclonal antibody 5D5 suppresses human cholangiocarcinoma xenograft growth via regulation of a SULF2-PDGFRbeta-YAP signaling axis.
     Hepatology. 2021 Mar 18. doi: 10.1002/hep.31817.
     PubMed     Abstract available
     
     
     
143. WADA Y, Shimada M, Yamamura K, Toshima T, et al
     A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma.
     Hepatology. 2021 Mar 16. doi: 10.1002/hep.31803.
     PubMed     Abstract available
     
     
     
144. CRISTOFERI L, Calvaruso V, Overi D, Vigano M, et al
     Accuracy of Transient Elastography in assessing fibrosis at diagnosis in naive patients with Primary Biliary Cholangitis: a dual cut-off approach.
     Hepatology. 2021 Mar 16. doi: 10.1002/hep.31810.
     PubMed     Abstract available
     
     
     
145. KENDRE G, Marhenke S, Lorz G, Becker D, et al
     The co-mutational spectrum determines the therapeutic response in murine FGFR2 fusion - driven cholangiocarcinoma.
     Hepatology. 2021 Mar 11. doi: 10.1002/hep.31799.
     PubMed     Abstract available
     
     
     
146. VAN WESSEL DBE, Thompson RJ, Gonzales E, Jankowska I, et al
     Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.
     Hepatology. 2021 Mar 5. doi: 10.1002/hep.31787.
     PubMed     Abstract available
     
     
     
147. ZHOU Y, Chen Y, Zhang X, Xu Q, et al
     Brg1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.
     Hepatology. 2021 Mar 2. doi: 10.1002/hep.31780.
     PubMed     Abstract available
     
     
     February 2021
148. CHIU M, Garabon J, Chen L, Karp N, et al
     Mevalonic Aciduria Associated with Intrahepatic Bile Duct Paucity.
     Hepatology. 2021 Feb 27. doi: 10.1002/hep.31778.
     PubMed     Abstract available
     
     
     
149. JOHNSON KM, Fischer RT, Holtmann GJ, Shah A, et al
     Letter to the editor: Oral vancomycin versus no therapy for pediatric primary sclerosing cholangitis.
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31764.
     PubMed     Abstract available
     
     
     
150. SHIOTA J, Samuelson LC, Razumilava N
     Hepatobiliary organoids and their applications for studies of liver health and disease: are we there yet?
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31772.
     PubMed     Abstract available
     
     
     
151. JOHN BV, Aitcheson G, Schwartz KB, Shabbir Khakoo N, et al
     Male Gender is Associated with Higher Rates of Liver-related Mortality in Primary Biliary Cholangitis and Cirrhosis.
     Hepatology. 2021 Feb 26. doi: 10.1002/hep.31776.
     PubMed     Abstract available
     
     
     
152. DAT NQ, Thuy LTT, Hieu VN, Hai H, et al
     6His-tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.
     Hepatology. 2021 Feb 11. doi: 10.1002/hep.31752.
     PubMed     Abstract available
     
     
     
153. MOHANTY SK, Donnelly B, Temple H, Ortiz-Perez A, et al
     HMGB1 release by cholangiocytes governs biliary atresia pathogenesis and correlates with increases in afflicted infants.
     Hepatology. 2021 Feb 8. doi: 10.1002/hep.31745.
     PubMed     Abstract available
     
     
     
154. JAVITT NB
     Letter to the Editor: Intravital dynamic and correlative imaging reveals diffusion-dominated canalicular and flow-augmented ductular bile flux.
     Hepatology. 2021 Feb 8. doi: 10.1002/hep.31746.
     PubMed     Abstract available
     
     
     
155. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Reply to "Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?"; multiple primaries vs liver metastases.
     Hepatology. 2021 Feb 7. doi: 10.1002/hep.31740.
     PubMed     Abstract available
     
     
     
156. ZHANG XF, Lv Y, Pawlik TM
     Letter to the editor: Does multiple intrahepatic cholangiocarcinoma worsen prognosis as "M1" stage?
     Hepatology. 2021 Feb 6. doi: 10.1002/hep.31741.
     PubMed     Abstract available
     
     
     
157. NASSER-GHODSI N, Mara K, Watt KD
     De novo Colorectal and Pancreatic Cancer in Liver Transplant Recipients: Identifying the Higher Risk Populations.
     Hepatology. 2021 Feb 5. doi: 10.1002/hep.31731.
     PubMed     Abstract available
     
     
     January 2021
158. ITOH A, Adams D, Huang W, Wu Y, et al
     Enoxacin upregulates microRNA biogenesis and downregulates cytotoxic CD8 T cell function in autoimmune cholangitis.
     Hepatology. 2021 Jan 19. doi: 10.1002/hep.31724.
     PubMed     Abstract available
     
     
     
159. LI J, Ye X, He S
     Letter to the Editor: Imaging monitoring of primary sclerosing cholangitis patients.
     Hepatology. 2021 Jan 11. doi: 10.1002/hep.31709.
     PubMed     Abstract available
     
     
     
160. ASSIS DN, Levy C
     Oral Vancomycin or Ursodeoxycholic acid for Pediatric Primary Sclerosing Cholangitis? The Uncontroversial Need for Randomized Controlled Trials.
     Hepatology. 2021 Jan 5. doi: 10.1002/hep.31702.
     PubMed     Abstract available
     
     
     
161. FENG GS, Hanley KL, Liang Y, Lin X, et al
     Improving the Efficacy of Liver Cancer Immunotherapy: The Power of Combined Preclinical and Clinical Studies.
     Hepatology. 2021;73 Suppl 1:104-114.
     PubMed     Abstract available
     
     
     
162. RIZVI S, Wang J, El-Khoueiry AB
     Liver Cancer Immunity.
     Hepatology. 2021;73 Suppl 1:86-103.
     PubMed    
     
     
     
163. LU X, Paliogiannis P, Calvisi DF, Chen X, et al
     Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
     Hepatology. 2021;73 Suppl 1:49-61.
     PubMed     Abstract available
     
     
     December 2020
164. KOUKOULIOTI E, Ziagaki A, Weber SN, Lammert F, et al
     Long-term colestyramine treatment prevents cholestatic attacks in refractory benign recurrent intrahepatic cholestasis type 1 disease.
     Hepatology. 2020 Dec 5. doi: 10.1002/hep.31671.
     PubMed     Abstract available
     
     
     November 2020
165. KNOOIHUIZEN SAI, Aday A, Lee WM
     Ketamine-Induced Sclerosing Cholangitis (KISC) in a Critically Ill Patient with COVID-19.
     Hepatology. 2020 Nov 23. doi: 10.1002/hep.31650.
     PubMed     Abstract available
     
     
     
166. MOUSA OY, Juran BD, McCauley BM, Vesterhus MN, et al
     Bile Acid Profiles in Primary Sclerosing Cholangitis and their Ability to Predict Hepatic Decompensation.
     Hepatology. 2020 Nov 23. doi: 10.1002/hep.31652.
     PubMed     Abstract available
     
     
     
167. KUNST RF, Verkade HJ, Oude Elferink RPJ, van de Graaf SFJ, et al
     Targeting the four pillars of enterohepatic bile salt cycling; lessons from genetics and pharmacology.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31651.
     PubMed     Abstract available
     
     
     
168. SATO K, Zhang W, Safarikia S, Isidan A, et al
     Organoids and spheroids as novel models for studying cholestatic liver injury and cholangiocarcinoma.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31653.
     PubMed     Abstract available
     
     
     
169. COLYN L, Barcena-Varela M, Alvarez-Sola G, Latasa MU, et al
     Dual targeting of G9a and DNMT1 for the treatment of experimental cholangiocarcinoma.
     Hepatology. 2020 Nov 22. doi: 10.1002/hep.31642.
     PubMed     Abstract available
     
     
     
170. MEADOWS V, Francis H
     DCLK1 in Cholangiocarcinoma: Is this the biomarker and target we've been looking for?
     Hepatology. 2020 Nov 11. doi: 10.1002/hep.31630.
     PubMed     Abstract available
     
     
     
171. SMETS L, Verbeek J, Korf H, van der Merwe S, et al
     Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate.
     Hepatology. 2020 Nov 3. doi: 10.1002/hep.31613.
     PubMed     Abstract available
     
     
     October 2020
172. XU Y, Zhu Y, Hu S, Xu Y, et al
     Hepatocyte nuclear factor 4alpha prevents the steatosis-to-NASH progression by regulating p53 and bile acid signaling.
     Hepatology. 2020 Oct 23. doi: 10.1002/hep.31604.
     PubMed     Abstract available
     
     
     
173. LAMARCA A, Santos-Laso A, Utpatel K, La Casta A, et al
     Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system.
     Hepatology. 2020 Oct 18. doi: 10.1002/hep.31598.
     PubMed     Abstract available
     
     
     
174. BRAGELMANN J, Barahona Ponce C, Marcelain K, Roessler S, et al
     Epigenome-wide analysis of methylation changes in the sequence of gallstone disease, dysplasia, and gallbladder cancer.
     Hepatology. 2020 Oct 5. doi: 10.1002/hep.31585.
     PubMed     Abstract available
     
     
     
175. KUNZMANN LK, Schoknecht T, Poch T, Henze L, et al
     Monocytes as Potential Mediators of Pathogen-Induced T-Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC).
     Hepatology. 2020;72:1310-1326.
     PubMed     Abstract available
     
     
     September 2020
176. NEVI L, Di Matteo S, Carpino G, Zizzari I, et al
     DCLK1, a putative novel stem cell marker in human cholangiocarcinoma.
     Hepatology. 2020 Sep 25. doi: 10.1002/hep.31571.
     PubMed     Abstract available
     
     
     
177. EATON JE, Welle CL, Bakhshi Z, Sheedy SP, et al
     Early cholangiocarcinoma detection with magnetic resonance imaging versus ultrasound in primary sclerosing cholangitis.
     Hepatology. 2020 Sep 25. doi: 10.1002/hep.31575.
     PubMed     Abstract available
     
     
     August 2020
178. LEUNG KK, James PD, Jaberi A, Hirschfield GM, et al
     Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding.
     Hepatology. 2020 Aug 11. doi: 10.1002/hep.31519.
     PubMed     Abstract available
     
     
     July 2020
179. DU Y, Khandekar G, Llewellyn J, Polacheck W, et al
     Reply to letter to the editor: Comment on "a bile duct-on-a-chip with organ-level functions".
     Hepatology. 2020 Jul 21. doi: 10.1002/hep.31471.
     PubMed     Abstract available
     
     
     
180. SCHULTHEISS C, Simnica D, Willscher E, Oberle A, et al
     Next-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis.
     Hepatology. 2020 Jul 21. doi: 10.1002/hep.31473.
     PubMed     Abstract available
     
     
     
181. LLEO A, Ma X, Gershwin ME, Invernizzi P, et al
     Letter to the Editor: Might Denosumab Fit in Primary Biliary Cholangitis Treatment?
     Hepatology. 2020;72:359-360.
     PubMed    
     
     
     April 2020
182. ADAMS JM, Huppert KA, Castro EC, Lopez MF, et al
     Sox9 Is a Modifier of the Liver Disease Severity in a Mouse Model of Alagille Syndrome.
     Hepatology. 2020;71:1331-1349.
     PubMed     Abstract available
     
     
     March 2020
183. LU ZN, Luo Q, Zhao LN, Shi Y, et al
     The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
     Hepatology. 2020;71:929-942.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Biliary Tract Diseases is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: